Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs
- 30 May 2001
- journal article
- clinical trial
- Published by Elsevier BV in Schizophrenia Research
- Vol. 50 (1-2), 79-88
- https://doi.org/10.1016/s0920-9964(00)00166-3
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Subjective Experience and Striatal Dopamine D2 Receptor Occupancy in Patients With Schizophrenia Stabilized by Olanzapine or RisperidoneAmerican Journal of Psychiatry, 2000
- Cognitive Dysfunction at Baseline Predicts Symptomatic 1-Year Outcome in First-Episode SchizophrenicsPsychopathology, 1999
- Determinants of Medication Compliance in Schizophrenia: Empirical and Clinical FindingsSchizophrenia Bulletin, 1997
- Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic‐induced deficitsActa Psychiatrica Scandinavica, 1994
- Neuroleptics and the neuroleptic‐induced deficit syndromeActa Psychiatrica Scandinavica, 1994
- Neuroleptic-induced deficit syndrome: old problem, new challengeJournal of Psychopharmacology, 1993
- Treatment with neuroleptics: the patient's perspectiveActa Psychiatrica Scandinavica, 1992
- Neuroleptic dysphoriaBiological Psychiatry, 1991
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970